SEARCH

SEARCH BY CITATION

References

  • Baillie TA, Rettie AE. (2011) Role of biotransformation in drug-induced toxicity: influence of intra- and inter-species differences in drug metabolism. Drug Metab Pharmacokinet 26:1529.
  • Berg AT, Berkovic SF, Brodie MJ, Buchhalter J, Cross JH, van Emde BW, Engel J, French J, Glauser TA, Mathern GW, Moshe SL, Nordli D, Plouin P, Scheffer IE. (2010) Revised terminology and concepts for organization of seizures and epilepsies: report of the ILAE Commission on Classification and Terminology, 2005-2009. Epilepsia 51:676685.
  • Brooks-Kayal AR, Bath KG, Berg AT, Galanopoulou AS, Holmes GL, Jensen FE, Kanner AM, O'Brien TJ, Whittemore VH, Winawer MR, Patel M, Scharfman HE. (2013) Issues related to symptomatic and disease modifying treatments affecting cognitive and neuropsychiatric comorbidities of epilepsy. Epilepsia 54(Suppl. 4):4460.
  • Engel JJ, Pitkänen A, Loeb JA, Dudek FE, Bertram EH III, Cole AJ, Moshé SL, Wiebe S, Fureman BE, Jensen FE, Mody I, Nehlig A, Vezzani A. (2013) Epilepsy Biomarkers. Epilepsia 54(Suppl. 4):6169.
  • Fang FC, Steen RG, Casadevall A. (2012) Misconduct accounts for the majority of retracted scientific publications. Proc Natl Acad Sci USA 109:1702817033.
  • Fisher RS, van Emde BW, Blume W, Elger C, Genton P, Lee P, Engel J Jr. (2005) Epileptic seizures and epilepsy: definitions proposed by the International League Against Epilepsy (ILAE) and the International Bureau for Epilepsy (IBE). Epilepsia 46:470472.
  • Freeman JM, Kossoff EH. (2010) Ketosis and the ketogenic diet, 2010: advances in treating epilepsy and other disorders. Adv Pediatr 57:315329.
  • Galanopoulou AS, Buckmaster PS, Staley KJ, Moshe SL, Perucca E, Engel J Jr, Loscher W, Noebels JL, Pitkanen A, Stables J, White HS, O'Brien TJ, Simonato M. (2012) Identification of new epilepsy treatments: issues in preclinical methodology. Epilepsia 53:571582.
  • Herper M. (2012) The Truly Staggering Cost Of Inventing New Drugs. Forbes Available at: http://www.forbes.com/sites/matthewherper/2012/02/10/the-truly-staggering-cost-of-inventing-new-drugs/ [Accessed January 20, 2013].
  • Hooijmans CR, Leenaars M, Ritskes-Hoitinga M. (2010) A gold standard publication checklist to improve the quality of animal studies, to fully integrate the Three Rs, and to make systematic reviews more feasible. Altern Lab Anim 38:167182.
  • Kadam SD, White AM, Staley KJ, Dudek FE. (2010) Continuous electroencephalographic monitoring with radio-telemetry in a rat model of perinatal hypoxia-ischemia reveals progressive post-stroke epilepsy. J Neurosci 30:404415.
  • Kahle MP, Bix GJ. (2012) Successfully Climbing the “STAIRs”: Surmounting Failed Translation of Experimental Ischemic Stroke Treatments. Stroke Res Treat 2012:374098.
  • Kaiser J. (2012) U.S. science budget Advocates win ‘exceptional’ boost for Alzheimer's research. Science 335:902.
  • Kilkenny C, Browne WJ, Cuthill IC, Emerson M, Altman DG. (2010) Improving bioscience research reporting: the ARRIVE guidelines for reporting animal research. PLoS Biol 8:e1000412.
  • Kimmelman J, Anderson JA. (2012) Should preclinical studies be registered? Nat Biotechnol 30:488489.
  • Lambrechts DA, Wieders LH, Aldenkamp AP, Kessels FG, de Kinderen RJ, Majoie MJ. (2012) The ketogenic diet as a treatment option in adults with chronic refractory epilepsy: efficacy and tolerability in clinical practice. Epilepsy Behav 23:310314.
  • Landis SC, Amara SG, Asadullah K, Austin CP, Blumenstein R, Bradley EW, Crystal RG, Darnell RB, Ferrante RJ, Fillit H, Finkelstein R, Fisher M, Gendelman HE, Golub RM, Goudreau JL, Gross RA, Gubitz AK, Hesterlee SE, Howells DW, Huguenard J, Kelner K, Koroshetz W, Krainc D, Lazic SE, Levine MS, Macleod MR, McCall JM, Moxley RT III, Narasimhan K, Noble LJ, Perrin S, Porter JD, Steward O, Unger E, Utz U, Silberberg SD. (2012) A call for transparent reporting to optimize the predictive value of preclinical research. Nature 490:187191.
  • Loscher W. (2007) The pharmacokinetics of antiepileptic drugs in rats: consequences for maintaining effective drug levels during prolonged drug administration in rat models of epilepsy. Epilepsia 48:12451258.
  • Loscher W, Honack D, Fassbender CP, Nolting B. (1991) The role of technical, biological and pharmacological factors in the laboratory evaluation of anticonvulsant drugs III. Pentylenetetrazole seizure models. Epilepsy Res 8:171189.
  • Lowenstein PR, Mandel RJ, Xiong WD, Kroeger K, Castro MG. (2007) Immune responses to adenovirus and adeno-associated vectors used for gene therapy of brain diseases: the role of immunological synapses in understanding the cell biology of neuroimmune interactions. Curr Gene Ther 7:347360.
  • Ludolph AC, Bendotti C, Blaugrund E, Chio A, Greensmith L, Loeffler JP, Mead R, Niessen HG, Petri S, Pradat PF, Robberecht W, Ruegg M, Schwalenstocker B, Stiller D, van den Berg L, Vieira F, von Horsten S. (2010) Guidelines for preclinical animal research in ALS/MND: a consensus meeting. Amyotroph Lateral Scler 11:3845.
  • McElroy-Cox C. (2009) Alternative approaches to epilepsy treatment. Curr Neurol Neurosci Rep 9:313318.
  • Nature Neuroscience E. (2013) Making methods clearer. Nat Neurosci 16:1.
  • Noe FM, Sorensen AT, Kokaia M, Vezzani A. (2012) Gene therapy of focal onset epilepsy using adeno-associated virus vector-mediated overexpression of neuropeptide Y. In Noebels JL, Avoli M, Rogawski MA, Olsen RW, Delgado-Escueta AV (Eds) Jasper's Basic Mechanisms of the Epilepsies National Center for Biotechnology Information. Bethesda, MD, U.S.A..
  • Pitkänen A, Nehlig A, Brooks-Kayal AR, Dudek FE, Friedman D, Galanopoulou AS, Jensen FE, Kaminski RM, Kapur J, Klitgaard H, Löscher W, Mody I, Schmidt D. (2013) Issues related to development of antiepileptogenic therapies. Epilepsia 54(Suppl. 4):3543.
  • Rigor in Science Working Group. (2011) Improving the Quality of NINDS-Supported Preclinical and Clinical Research through Rigorous Study Design and Transparent Reporting.
  • Ross JS, Tse T, Zarin DA, Xu H, Zhou L, Krumholz HM. (2012) Publication of NIH funded trials registered in ClinicalTrials.gov: cross sectional analysis. BMJ 344:d7292.
  • Shetty AK. (2012) Neural Stem Cell Therapy for Temporal Lobe Epilepsy. In Noebels L, Avoli M, Rogawski MA, Olsen RW, Delgado-Escueta AV (Eds) Jasper's Basic Mechanisms of the Epilepsies. National Center for Biotechnology Information (US), Bethesda, MD.
  • Shineman DW, Basi GS, Bizon JL, Colton CA, Greenberg BD, Hollister BA, Lincecum J, Leblanc GG, Lee LB, Luo F, Morgan D, Morse I, Refolo LM, Riddell DR, Scearce-Levie K, Sweeney P, Yrjanheikki J, Fillit HM. (2011) Accelerating drug discovery for Alzheimer's disease: best practices for preclinical animal studies. Alzheimers Res Ther 3:28.
  • Sorensen AT, Kanter-Schlifke I, Carli M, Balducci C, Noe F, During MJ, Vezzani A, Kokaia M. (2008) NPY gene transfer in the hippocampus attenuates synaptic plasticity and learning. Hippocampus 18:564574.
  • Steward O, Popovich PG, Dietrich WD, Kleitman N. (2012) Replication and reproducibility in spinal cord injury research. Exp Neurol 233:597605.
  • The Cochrane Collaboration. (2012) The Cochrane Collaboration Supports Free Access to all Data from all Clinical Trials.
  • The NIH/NINDS Anticonvulsant Screening Program (ASP): recommendations from the working group's. (2012) Review of the Program. Epilepsia 53:18371839.
  • Vezzani A, Balosso S, Ravizza T. (2012) Inflammation and epilepsy. Handb Clin Neurol 107:163175.
  • Vugmeyster Y, Harrold J, Xu X. (2012) Absorption, distribution, metabolism, and excretion (ADME) studies of biotherapeutics for autoimmune and inflammatory conditions. AAPS J 14:714727.
  • Weinberg MS, McCown TJ. (2013) Current prospects and challenges for epilepsy gene therapy. Exp Neurol 244:2735.
  • White AM, Williams PA, Ferraro DJ, Clark S, Kadam SD, Dudek FE, Staley KJ. (2006) Efficient unsupervised algorithms for the detection of seizures in continuous EEG recordings from rats after brain injury. J Neurosci Methods 152:255266.
  • Wilcox KS, Dixon-Salazar T, Sills GJ, Ben-Menachem E, White HS, Porter RJ, Dichter MA, Moshé SL, Noebels JL, Privitera M, Rogawski MA. (2013) Issues related to development of new anti-seizure treatments. Epilepsia 54(Suppl. 4):2434.
  • Williams PA, White AM, Clark S, Ferraro DJ, Swiercz W, Staley KJ, Dudek FE. (2009) Development of spontaneous recurrent seizures after kainate-induced status epilepticus. J Neurosci 29:21032112.